Resistance Data That Arrives With the ID.
Carbapenemases, MRSA, vancomycin, ESBL, sulfonamide, and trimethoprim resistance — automatically reflexed from any positive bacterial primary panel.
Phenotypic susceptibility takes 48–72 hours after a positive culture. By the time it lands, empirical therapy is locked in and stewardship is reacting, not guiding.
Eight actionable resistance genes — mecA/C, VanA, VanB, KPC, NDM, CTX-M, Sul1/2, DfrA — reflexed automatically and reported alongside the organism ID in the same 24–48 hour window.
The clinical weight behind this panel.
Industry statistics from public-health bodies and peer-reviewed literature — context for why this testing matters.
Genotype anticipates phenotype faster than culture-based AST.
Figures reflect publicly reported epidemiology and clinical literature for context only. They are not performance claims for the Chaseville Labs assay. See individual citations from the U.S. Centers for Disease Control and Prevention, World Health Organization, National Institutes of Health, and peer-reviewed journals.
Conditions, syndromes & infections covered.
The clinical scenarios where this panel is the right call — built around the differential your providers are actually working through.
Multi-Drug Resistant Gram-Negatives
2KPC, VIM, NDM, IMP, OXA-48-like — the WHO's highest-priority resistance threats. Often fatal in bloodstream infection.
Extended-spectrum beta-lactamases — common in E. coli and Klebsiella UTI and bloodstream infections.
Gram-Positive Resistance
2Direct gene-level confirmation of methicillin resistance — no waiting for phenotypic susceptibility.
Enterococcus faecium and E. faecalis with vancomycin resistance — a feared healthcare-associated pathogen.
Other Actionable Resistance
3Predicts failure of ciprofloxacin, levofloxacin, and moxifloxacin — common in recurrent UTI and travel-associated infections.
Predicts trimethoprim-sulfamethoxazole (Bactrim) failure — relevant in UTI, SSTI, and prophylaxis.
The patient not getting better on standard antibiotics — culture eventually shows resistance, but the patient has already deteriorated.
8 targets, resolved from a single specimen.
Each organism below is reported individually as Detected, Not Detected, or Inconclusive — grouped here by pathogen class for clinical scanability.
Carbapenem Resistance
2 targetsMRSA Marker
1 targetVancomycin Resistance
2 targetsSulfonamide Resistance
1 targetESBL
1 targetTrimethoprim Resistance
1 targetCulture was built for a different century.
Multiplex real-time PCR resolves what culture and rapid antigen miss — fastidious organisms, polymicrobial infections, viruses, and resistance markers — from a single specimen.
Culture & rapid antigen
- 3–5 daysPatient empirically treated before any answer arrives
- Misses fastidious & viral organismsNo growth ≠ no infection
- Single-organism biasPolymicrobial infections under-reported
- No resistance dataSusceptibilities arrive a day later, if at all
- Specimen-quality dependentPre-treated patients culture negative
ABR Reflex on Bio-Rad CFX384
- 24–48 hoursMost reports back the next clinical day
- 8 targets, one runBacterial, viral, fungal, and parasitic in a single multiplex
- Detects what culture can'tFastidious organisms, viruses, and polymicrobial infections, all reported individually
- Validated LDTCLIA-certified, internally controlled, per-target Detected / Not Detected reporting
Per-target results, with clinical context.
Every analyte is reported individually as Detected, Not Detected, or Inconclusive. What a Detected result means clinically depends on which category the target falls into:
KPC, VIM, NDM, IMP, and OXA-48-like detection indicates carbapenem-resistant Enterobacterales — contact precautions, public-health notification, and consideration of newer beta-lactam/beta-lactamase inhibitors or cefiderocol.
mecA/C detection confirms methicillin resistance — switch from beta-lactams to vancomycin, daptomycin, linezolid, or ceftaroline depending on site.
VanA/VanB detection indicates vancomycin-resistant Enterococcus — treat with linezolid or daptomycin and apply contact precautions.
Sul1/Sul2 detection predicts TMP-SMX failure for the carried organism.
CTX-M detection identifies extended-spectrum beta-lactamase producers — avoid third-generation cephalosporins; carbapenems or BL/BLI combinations are preferred.
DfrA detection predicts trimethoprim failure and supports alternative agents for UTI or skin/soft-tissue infection.